A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.

Zhang Y, Li S, Wang Y, Lu Y, Xu Y, Rao Q, Wang H, Xing H, Tian Z, Tang K, Lv L, Wang M, Wang J
Exp Hematol Oncol. 2022 Mar 22;11(1):15. doi: 10.1186/s40164-022-00270-5. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.